{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:05:01Z","timestamp":1789635901476,"version":"4.0.0"},"reference-count":38,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T00:00:00Z","timestamp":1789257600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background: Anthracycline-induced cardiotoxicity remains a major clinical challenge in oncology. The association between statin use and pulmonary hemodynamic changes during anthracycline chemotherapy remains largely unexplored. Methods: The primary endpoint was change in left ventricular ejection fraction from baseline to 12 months. Secondary endpoints included changes in left ventricular end-systolic volume index and mean e\u2019 velocity. Exploratory endpoints included changes in other diastolic parameters, all estimated systolic pulmonary artery pressure (SPAP)-derived variables, and the descriptive incidence of cancer therapeutics-related cardiac dysfunction (CTRCD). Analyses included multivariable linear regression, 1:1 propensity score matching with baseline echocardiographic parameters included in the matching model, and multiple imputation for missing SPAP data. Results: After confounder adjustment, statin use was independently associated with a milder decline in mean e\u2019 velocity (\u03b2 = 0.75 cm\/s, 95% CI 0.41 to 1.09, p &lt; 0.001) and a smaller reduction in E\/A ratio (\u03b2 = 0.06, 95% CI 0.01 to 0.11, p = 0.02). No significant between-group difference was observed for adjusted ejection fraction change (\u03b2 = 0.28%, 95% CI \u22121.11 to 1.66, p = 0.694). Statin use was associated with lower relative change amplitude of estimated SPAP (\u03b2 = \u22124.55%, 95% CI \u22127.34 to \u22121.76, p = 0.001), with no significant effect on signed mean change. A descriptive component analysis showed a smaller signed mean change in estimated right atrial pressure in the statin group, with no significant difference in tricuspid regurgitant pressure gradient change. This comparison cannot mathematically decompose the absolute-change SPAP endpoint. The incidence of study-defined CTRCD was numerically lower in the statin group (1.25% vs. 4.8%, OR 0.25, 95% CI 0.05 to 1.28, p = 0.15), but this difference was not statistically significant and the study was underpowered for this clinical endpoint. Conclusions: In this retrospective cohort, concomitant statin therapy was associated with smaller changes in diastolic parameters and lower relative change amplitude of estimated SPAP between baseline and 12 month follow-up. No significant independent association with left ventricular systolic function was observed after multivariable adjustment. These hypothesis-generating findings require confirmation in appropriately powered prospective multicenter studies before any clinical implications can be considered.<\/jats:p>","DOI":"10.3390\/jcm15187105","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T12:09:51Z","timestamp":1789387791000},"page":"7105","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Statin Co-Administration Is Associated with Subclinical Echocardiographic Alterations and Relative Change Amplitude of Estimated Systolic Pulmonary Artery Pressure After Anthracycline Chemotherapy: A Retrospective Cohort Study"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5508-5163","authenticated-orcid":false,"given":"Shouzhi","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Ultrasound, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6708-2991","authenticated-orcid":false,"given":"Ying","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First People\u2019s Hospital of Hefei, The Third Affiliated Hospital of Anhui Medical University, Hefei 230061, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0855-7028","authenticated-orcid":false,"given":"Lei","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"data-curation","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3789-7343","authenticated-orcid":false,"given":"Jiawei","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"resources","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3250-3960","authenticated-orcid":false,"given":"Chuang","family":"Yin","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9725-3781","authenticated-orcid":false,"given":"Nianan","family":"He","sequence":"additional","affiliation":[{"name":"Department of Ultrasound, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat. Med."},{"key":"ref_2","first-page":"309","article-title":"Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management","volume":"66","author":"Curigliano","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"oyaf370","DOI":"10.1093\/oncolo\/oyaf370","article-title":"Association of early dexrazoxane with reduced cardiotoxicity risk in sarcoma patients treated with anthracycline chemotherapy","volume":"30","author":"Jang","year":"2025","journal-title":"Oncologist"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s13691-026-00848-4","article-title":"Dexrazoxane reduces antithrombin activity: A case series","volume":"15","author":"Nagano","year":"2026","journal-title":"Int. Cancer Conf. J."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e012518","DOI":"10.1161\/CIRCHEARTFAILURE.124.012518","article-title":"TAPSE\/sPAP Ratio to Improve Risk Assessment in Pulmonary Arterial Hypertension","volume":"18","author":"Badagliacca","year":"2025","journal-title":"Circ. Heart Fail."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3390\/pathophysiology29010012","article-title":"sPAP\/PAAT Ratio as a New Index of Pulmonary Vascular Load: A Study in Normal Subjects and Ssc Patients with and without PH","volume":"29","author":"Serra","year":"2022","journal-title":"Pathophysiology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ejim.2024.04.007","article-title":"Cardio-protective effects of statins in patients undergoing anthracycline-based chemotherapy: An updated meta-analysis of randomized controlled trials","volume":"126","author":"Felix","year":"2024","journal-title":"Eur. J. Intern. Med."},{"key":"ref_9","first-page":"1395","article-title":"Statins to mitigate cardiotoxicity in cancer patients treated with anthracyclines and\/or trastuzumab: A systematic review and meta-analysis","volume":"32","author":"Obasi","year":"2021","journal-title":"Cancer Causes Control"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Xu, G., Zhang, R., Huang, W., Du, X., and Xu, W. (2025). Comparative effectiveness of statins for chronic obstructive pulmonary disease patients with pulmonary hypertension: Systematic review and network meta-analysis. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1640270"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1164\/rccm.2009111-699OC","article-title":"Simvastatin as a treatment for pulmonary hypertension trial","volume":"181","author":"Wilkins","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","article-title":"Pleiotropic effects of statins","volume":"45","author":"Liao","year":"2005","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","article-title":"Pleiotropic Effects of Statins on the Cardiovascular System","volume":"120","author":"Oesterle","year":"2017","journal-title":"Circ. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCRESAHA.115.306532","article-title":"RhoA\/Rho-Kinase in the Cardiovascular System","volume":"118","author":"Shimokawa","year":"2016","journal-title":"Circ. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1001\/jama.2023.11887","article-title":"Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial","volume":"330","author":"Neilan","year":"2023","journal-title":"JAMA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/ehjcvp\/pvad031","article-title":"Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines","volume":"9","author":"Thavendiranathan","year":"2023","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"EVIDoa2200097","DOI":"10.1056\/EVIDoa2200097","article-title":"Statins and Left Ventricular Ejection Fraction Following Doxorubicin Treatment","volume":"1","author":"Hundley","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e018393","DOI":"10.1161\/JAHA.119.018393","article-title":"Statin Exposure and Risk of Heart Failure After Anthracycline- or Trastuzumab-Based Chemotherapy for Early Breast Cancer: A Propensity Score\u2014Matched Cohort Study","volume":"10","author":"Bobrowski","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"27","author":"Plana","year":"2014","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ehjci\/jev014","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"16","author":"Lang","year":"2015","journal-title":"Eur. Heart J.-Cardiovasc. Imaging"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.echo.2016.01.011","article-title":"Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"29","author":"Nagueh","year":"2016","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.echo.2025.01.006","article-title":"Guidelines for the Echocardiographic Assessment of the Right Heart in Adults and Special Considerations in Pulmonary Hypertension: Recommendations from the American Society of Echocardiography","volume":"38","author":"Mukherjee","year":"2025","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_24","unstructured":"Chinese Society of Cardiology, Chinese Medical Association, and Editorial Board of Chinese Journal of Cardiology (2025). Expert consensus statement on prevention and management of cancer therapy-related cardiac dysfunction. Zhonghua Xin Xue Guan Bing Za Zhi, 53, 855\u2013871."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1136\/bmj.323.7321.1123","article-title":"Statistics notes: Analysing controlled trials with baseline and follow up measurements","volume":"323","author":"Vickers","year":"2001","journal-title":"BMJ"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivar. Behav. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1037\/a0020761","article-title":"A general approach to causal mediation analysis","volume":"15","author":"Imai","year":"2010","journal-title":"Psychol. Methods"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1016\/S0735-1097(25)03271-1","article-title":"Exploring the Use of Statins for the Prevention of Anthracycline Induced Cardiotoxicity: A Systematic Review and Meta-Analysis","volume":"85","author":"Bano","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.cjco.2022.08.006","article-title":"Statins Protect Against Early Stages of Doxorubicin-induced Cardiotoxicity Through the Regulation of Akt Signaling and SERCA2","volume":"4","author":"Dadson","year":"2022","journal-title":"CJC Open"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s11912-024-01579-6","article-title":"Statins for the Primary Prevention of Anthracycline Cardiotoxicity: A Comprehensive Review","volume":"26","author":"Bhasin","year":"2024","journal-title":"Curr. Oncol. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1634\/theoncologist.2014-0500","article-title":"Diastolic Dysfunction Following Anthracycline-Based Chemotherapy in Breast Cancer Patients: Incidence and Predictors","volume":"20","author":"Serrano","year":"2015","journal-title":"Oncologist"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.echo.2025.03.011","article-title":"Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography and for Heart Failure With Preserved Ejection Fraction Diagnosis: An Update From the American Society of Echocardiography","volume":"38","author":"Nagueh","year":"2025","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Eakin, A.J., Mc Erlain, T., Burke, A., Eaton, A., Tipping, N., Allocca, G., and Branco, C.M. (2020). Circulating Levels of Epirubicin Cause Endothelial Senescence While Compromising Metabolic Activity and Vascular Function. Front. Cell Dev. Biol., 8.","DOI":"10.3389\/fcell.2020.00799"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1161\/CIRCULATIONAHA.124.071774","article-title":"Endothelial Transcription Factor EB Protects Against Doxorubicin-Induced Endothelial Toxicity and Cardiac Dysfunction","volume":"153","author":"Du","year":"2026","journal-title":"Circulation"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Faggiano, A., Gherbesi, E., Giordano, C., Gamberini, G., Vicenzi, M., Cuspidi, C., Carugo, S., Cipolla, C.M., and Cardinale, D.M. (2024). Anthracycline-Induced Subclinical Right Ventricular Dysfunction in Breast Cancer Patients: A Systematic Review and Meta-Analysis. Cancers, 16.","DOI":"10.3390\/cancers16223883"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1016\/j.jacc.2018.12.076","article-title":"Anatomy, Function, and Dysfunction of the Right Ventricle: JACC State-of-the-Art Review","volume":"73","author":"Sanz","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_37","first-page":"898","article-title":"Rosuvastatin intensifies the beneficial effects of rho-kinase inhibitor in reversal of monocrotaline-induced pulmonary hypertension","volume":"12","author":"Owczarek","year":"2016","journal-title":"Arch. Med. Sci. AMS"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1161\/01.CIR.97.12.1129","article-title":"Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors","volume":"97","author":"Laufs","year":"1998","journal-title":"Circulation"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/18\/7105\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:40:04Z","timestamp":1789634404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/18\/7105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,13]]},"references-count":38,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jcm15187105"],"URL":"https:\/\/doi.org\/10.3390\/jcm15187105","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,13]]}}}